Ibrutinib 560 mg
OASIS-II
Phase 2 small_molecule active
Quick answer
Ibrutinib 560 mg for Mantle Cell Lymphoma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Mantle Cell Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active